• The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

  NCT06450392

  RecruitingInterventionalPhase 4Updated Dec 16, 2025
• Use of Tranexamic Acid in Blepharoplasties

  NCT04724772

  WithdrawnInterventionalPhase 3Updated Jul 23, 2024
• The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery

  NCT05672407

  WithdrawnInterventionalPhase 4Updated Sep 21, 2023
• Topical Tranexamic Acid Application in Rhinoplasty

  NCT05326139

  CompletedInterventionalPhase 4Updated Apr 13, 2022
• Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

  NCT05774717

  RecruitingInterventionalPhase 1Updated May 7, 2026
• The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery

  NCT06270407

  RecruitingInterventionalPhase 4Updated Aug 14, 2026

ClinicalTrials.gov ID

NCT04951128

Lead Sponsor

Consultants in Ophthalmic and Facial Plastics SurgeryOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 4

Enrollment

50Estimated

Last Update Posted

Jul 6, 2021Actual

Start Date

Aug 1, 2021Estimated

Primary Completion Date

Dec 31, 2021Estimated

Completion Date

Jul 1, 2022Estimated

Official Title

The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery

Brief Summary

Tranexamic acid (TXA) is a synthetic inhibitor of plasminogen lysine receptor that has used to reduce intra-operative bleeding in a number of clinical scenarios. Anecdotally, TXA has used by plastic surgeons to reduce post-operative bruising. To date, there is limited data to valid the benefits and to evaluate the side effects of TXA. The objective of this study is to evaluate the effect of local TXA on edema and ecchymosis in eyelid surgery.

Detailed Description

Tranexamic acid (TXA) is a synthetic reversible competitive inhibitor to plasminogen lysine receptor, which prevents plasmin formation and stabilizes the fibrin matrix, thus reduce bleeding. Recent studies have demonstrated the antifibrinolytic benefits of TXA in a number of clinical scenarios, including heavy menstrual bleeding, traumatic hemorrhage, elective cesarean section, total knee arthroplasty, coronary artery surgery, spinal deformity surgery, orthognathic surgery, transurethral prostate resection, aneurysmal subarachnoid hemorrhage, epistaxis, and hemoptysis.

Anecdotally, TXA has been used by plastic surgeons to reduce postoperative bruising. However, there is a paucity of clinical data on TXA use in plastic surgery, and the results are inconsistent. In a prospective randomized controlled trial evaluating local TXA in upper blepharoplasty, Sagiv et al reported no intraoperative blood loss, surgeon's assessment of hemostasis, and periocular ecchymosis size on postoperative day 1. Butz and Geldner reviewed their experience placing TXA-soaked pledgets in 57 patients who underwent face lift18. They identified only 1 patient who had post-operative hematoma and they reported no systemic complications from TXA use. In a randomized control trial evaluating topical TXA in reduction mammoplasty, Ausen et al reported 39% reduction of postoperative fluid drainage on the treatment side. In a study evaluating oral TXA and cortisone effect in rhinoplasty, Sakalliogu et al reported significant reduction of intraoperative bleeding and postoperative ecchymosis/edema in patients who underwent rhinoplasty. Further study is warranted to evaluate the use to TXA in plastic surgery. The objective of this study is to evaluate the effect of local TXA on edema and ecchymosis in eyelid surgery.

• Edema
• Ecchymosis; Eyelid

• Tranexamic acid injection
• Local anesthetic control

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Older than 18 years old
• Undergo bilateral upper/lower eyelid blepharoplasty, bilateral upper eyelid ptosis repair, or a combination of the above procedures
• Additional concurrent forehead/brow or upper/lower eyelids surgeries may be included if bilateral

Exclusion Criteria:

• Prior eyelid surgery
• Anticoagulant or antiplatelet use, including aspirin, within 7 days prior to surgery
• Patient who is currently pregnant or breast feeding
• Patient with color vision deficiency
• TXA allergy
• History of bleeding disorder
• History of clotting disorder
• History of seizure
• Have active nausea/vomiting/gastrointestinal symptoms
• Have active intracranial bleeding
• Have active periocular ecchymosis or edema prior to surgery

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Single Group Assignment

Masking

Triple

Lead Sponsor

Consultants in Ophthalmic and Facial Plastics SurgeryOTHER

almalik@houstonmethodist.org713-441-8843